The Lancet Oncology· Saby George, Ulka Vaishampayan, Alan Hutson, Adrienne Groman, Roberto Pili, Kelly Green, Laurie Herbst, Rushka Kallicharan-Smith, Ann-Marie DiRaddo, Elongia Farrell, Dharmesh Gopalakrishnan, Elisabeth Heath, Elizabeth Wulff, Deepak Kilari, Leonard Appleman, Rahul Parikh·· 4 小时前评分49
Pazopanib 与 bevacizumab 交替治疗初治转移性透明细胞肾细胞癌患者：多中心单臂1/2期试验
[Articles] Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial
导读
多中心单臂1/2期试验显示，未接受治疗的转移性透明细胞肾细胞癌患者交替使用 Pazopanib 与 bevacizumab，在以预后良好风险组为主的患者中呈现有前景的抗肿瘤活性。1期确定了安全RP2D，结果仍需3期随机对照试验确认。
来源：The Lancet Oncology · thelancet.com